Public Protocol
Platform

Guide

Guidelines on long-acting injectable cabotegravir for HIV prevention

External resource. Not made or verified by Public Protocol.

WHO guidelines of July 2022 stating that long-acting injectable cabotegravir may be offered as an additional HIV prevention option for people at substantial risk.

Go to the source

https://www.who.int/publications/i/item/9789240054097

Maintainer
World Health Organization
Licence, as stated at its source
CC BY-NC-SA 3.0 IGO
Open or commercial
Open
Maturity
EstablishedOur reading, 16 November 2026
Safety
S3medical
Review
Listed 16 November 2026by Public Protocol editors
Checked
16 November 2026
Next check due
16 May 2027
Steward
Public Protocol editors

Where it sits in the blueprint

Stages

Learn

Elements it supports

Recorded when its maker or a reviewer places it against single elements.

Context

Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.

Verification

No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.

Record

How it came in

Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.

Licence

CC BY-NC-SA 3.0 IGO. Read at https://www.who.int/publications/i/item/9789240054097. How licences are recorded